Login to Your Account



Rigel Tumbles on Phase III RA Failure; Lilly Drug Misses, Too

By Catherine Shaffer
Staff Writer

Thursday, December 13, 2012
AstraZeneca plc's top-line results from a Phase IIb study of fostamatinib in rheumatoid arthritis showed that the drug was superior to placebo at six weeks, but it fell short of a secondary goal of noninferiority against Humira, sending shares of partner Rigel Pharmaceuticals Inc. plunging by almost 35 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription